WFT 3
Alternative Names: WFT-3Latest Information Update: 29 Sep 2021
At a glance
- Originator Walking Fish Therapeutics
- Class Cell therapies; Gene therapies; Proteins
- Mechanism of Action Cell replacements; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 20 Sep 2021 WFT 3 is available for licensing as of 20 Sep 2021. https://www.walkingfishtx.com/contact-us
- 20 Sep 2021 Preclinical trials in Unspecified in USA (Parenteral) (Walking Fish Therapeutics website, September 2021)